221 related articles for article (PubMed ID: 28427212)
41. Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer.
Tsai YF; Tseng LM; Hsu CY; Yang MH; Chiu JH; Shyr YM
PLoS One; 2017; 12(6):e0178173. PubMed ID: 28604807
[TBL] [Abstract][Full Text] [Related]
42. β-Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells.
Ye X; Wu F; Wu C; Wang P; Jung K; Gopal K; Ma Y; Li L; Lai R
Cell Signal; 2014 Mar; 26(3):492-501. PubMed ID: 24291232
[TBL] [Abstract][Full Text] [Related]
43. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
44. [Role of tenascin С in triple-negative breast cancer].
Popova OP; Bogomazova SY; Ivanov AA
Arkh Patol; 2017; 79(5):10-15. PubMed ID: 29027523
[TBL] [Abstract][Full Text] [Related]
45. Nodal signaling promotes a tumorigenic phenotype in human breast cancer.
Kirsammer G; Strizzi L; Margaryan NV; Gilgur A; Hyser M; Atkinson J; Kirschmann DA; Seftor EA; Hendrix MJ
Semin Cancer Biol; 2014 Dec; 29():40-50. PubMed ID: 25073112
[TBL] [Abstract][Full Text] [Related]
46. The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.
Fernandez AI; Geng X; Chaldekas K; Harris B; Duttargi A; Berry VL; Berry DL; Mahajan A; Cavalli LR; Győrffy B; Tan M; Riggins RB
Breast Cancer Res Treat; 2020 Feb; 179(3):585-604. PubMed ID: 31741180
[TBL] [Abstract][Full Text] [Related]
47. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
48. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
[TBL] [Abstract][Full Text] [Related]
49. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
[TBL] [Abstract][Full Text] [Related]
50. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.
Lustig LC; Dingar D; Tu WB; Lourenco C; Kalkat M; Inamoto I; Ponzielli R; Chan WCW; Shin JA; Penn LZ
Oncogene; 2017 Dec; 36(49):6830-6837. PubMed ID: 28806396
[TBL] [Abstract][Full Text] [Related]
51. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
Park SH; Chung YM; Ma J; Yang Q; Berek JS; Hu MC
Oncotarget; 2016 Jul; 7(27):42110-42125. PubMed ID: 27283899
[TBL] [Abstract][Full Text] [Related]
53. LIPH promotes metastasis by enriching stem-like cells in triple-negative breast cancer.
Zhang Y; Zhu X; Qiao X; Gu X; Xue J; Han Y; Sun L; Cui M; Liu C
J Cell Mol Med; 2020 Aug; 24(16):9125-9134. PubMed ID: 32618099
[TBL] [Abstract][Full Text] [Related]
54. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
[TBL] [Abstract][Full Text] [Related]
55. [Vascular endothelial growth factor promotes cancer stemness of triple-negative breast cancer via MAPK/ERK pathway].
Wang L; Zhao L; Zhang L; Jing X; Zhang Y; Shao S; Zhao X; Luo M
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1484-1491. PubMed ID: 34755663
[TBL] [Abstract][Full Text] [Related]
56. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
57. Breast tumour cell subpopulations with expression of the MYC and OCT4 proteins.
Litviakov NV; Bychkov VA; Stakheeva MN; Ibragimova MK; Tsyganov MM; Gaptulbarova KA; Tashireva LA; Bondar LN; Garbukov EY; Slonimskaya EM
J Mol Histol; 2020 Dec; 51(6):717-728. PubMed ID: 33037978
[TBL] [Abstract][Full Text] [Related]
58. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
59. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
60. Phosphorylation of Sox2 at Threonine 116 is a Potential Marker to Identify a Subset of Breast Cancer Cells with High Tumorigenecity and Stem-Like Features.
Gupta N; Gopal K; Wu C; Alshareef A; Chow A; Wu F; Wang P; Ye X; Bigras G; Lai R
Cancers (Basel); 2018 Feb; 10(2):. PubMed ID: 29401647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
